<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Immunohistochemical changes associated with development of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> offer potential areas of intervention to prevent and manage <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>AIMS: To assess the role of cyclooxygenase 2, caudal-type homeobox transcription factor 2 and cell division cycle 2/cyclin-dependent kinase 1 in the Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath>-<z:mpath ids='MPATH_589'>dysplasia</z:mpath>-<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> sequence </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: Specimens from 46 patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (39% without <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, 33% with <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and 28% with <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>) were stained for cyclooxygenase 2, caudal-type homeobox transcription factor 2 and cell division cycle 2 </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Cyclooxygenase 2: No expression differences between groups were found, except for <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> (p=0.04) </plain></SENT>
<SENT sid="4" pm="."><plain>Caudal-type homeobox transcription factor 2: Nuclear positivity decreased from <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> without <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (71.6%), to <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with low grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (35.3%), to <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with high grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (17.14%); in <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> these percentages were intermediate between high and low grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (30.5%) </plain></SENT>
<SENT sid="5" pm="."><plain>Cell division cycle 2: Expression on deeper glandular structures was 40% in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> without <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, 55.47% in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and 63.84% in <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, with no statistical differences between groups </plain></SENT>
<SENT sid="6" pm="."><plain>Concerning cells of the superficial layer, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with low grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> expressed focal positivity (p=0.0001 vs. no <z:mpath ids='MPATH_589'>dysplasia</z:mpath>); <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with high grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> displayed diffuse positivity (p=0.0001 vs. no <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and low grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>) </plain></SENT>
<SENT sid="7" pm="."><plain>A diffuse positivity was found in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (p=0.0001 vs. no <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and low grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Further evaluation of cyclooxygenase 2, cell division cycle 2 and caudal-type homeobox transcription factor 2, in association with <z:mp ids='MP_0000002'>morphology</z:mp>, might help to improve the accuracy of diagnosis and be useful for the clinical-pathological assessment of patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
</text></document>